PRESS RELEASE published on 02/20/2025 at 07:30, 9 months 13 days ago Inside Information / Other news releases Sensorion announces participation in investor conferences in March. CEO and CFO will attend Cowen and Leerink events to present company updates and meet investors Biotechnology CFO Investor Conferences CEO Sensorion
BRIEF published on 02/18/2025 at 07:35, 9 months 15 days ago Sensorion announces its participation in congresses in March 2025 Biotechnology Sensorion Hearing Therapies Medical Innovations Congress 2025
PRESS RELEASE published on 02/18/2025 at 07:30, 9 months 15 days ago Inside Information / Other news releases Sensorion announces participation in upcoming congresses in March to present on innovative biologics and manufacturing challenges for hearing loss disorders Sensorion Hearing Loss Biologics Congresses Manufacturing Challenges
BRIEF published on 02/12/2025 at 11:35, 9 months 21 days ago Sensorion to Participate in ARO 48th Annual Midwinter Meeting Sensorion Hearing Loss ARO Meeting GJB2-GT Therapy Biotech Conference
PRESS RELEASE published on 02/12/2025 at 11:30, 9 months 21 days ago Inside Information / Other news releases Sensorion announces participation in ARO 48th Annual Midwinter Meeting with focus on gene therapy for deafness. Details of presentations by Sensorion executives included Gene Therapy Sensorion ARO Meeting Deafness Sensorion Executives
BRIEF published on 12/27/2024 at 07:35, 11 months 9 days ago Sensorion Completes Enrollment for Audiogene Phase 1/2 Trial Gene Therapy Sensorion Hearing Loss SENS-501 Audiogene Trial
PRESS RELEASE published on 12/27/2024 at 07:30, 11 months 9 days ago Inside Information / Other news releases Sensorion completes enrollment of the first cohort in the Audiogene Phase 1/2 gene therapy clinical trial, targeting infants with hearing loss disorders Gene Therapy Clinical Trial Sensorion Hearing Loss Disorders Audiogene
BRIEF published on 12/18/2024 at 07:35, 11 months 18 days ago Sensorion Reports Positive Preliminary Results for SENS-501 Gene Therapy Clinical Trial SENS-501 Congenital Deafness Biotechnological Innovation
PRESS RELEASE published on 12/18/2024 at 07:30, 11 months 18 days ago Inside Information / Other news releases Sensorion reports positive safety data and behavioral changes in toddlers from the Audiogene Phase 1/2 Gene Therapy Clinical Trial. Plans KOL event in 2025 for further discussion Gene Therapy Clinical Trial Sensorion Hearing Loss Audiogene
BRIEF published on 11/06/2024 at 07:35, 1 year ago Sensorion to Join Key Investor Conferences in November 2024 Biotechnology Investor Conferences Sensorion Hearing Loss Therapies Gene Therapy Development
Published on 12/05/2025 at 15:35, 14 minutes ago XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:00, 49 minutes ago Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 49 minutes ago Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 49 minutes ago Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 15:38, 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/05/2025 at 15:36, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Published on 12/05/2025 at 15:35, 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/05/2025 at 15:33, 15 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/05/2025 at 15:32, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Alphawave IP Group plc
Published on 12/05/2025 at 15:10, 38 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 7 hours 4 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 21 hours 49 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 22 hours 4 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 22 hours 5 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
